Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002052524-25-000003
Filing Date
2025-09-18
Accepted
2025-09-18 21:29:01
Documents
1
Period of Report
2025-09-16

Document Format Files

Seq Description Document Type Size
1 form4-09192025_010957.html 4  
1 form4-09192025_010957.xml 4 6033
  Complete submission text file 0002052524-25-000003.txt   7501
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Issuer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169
Business Address
Gentilcore Douglas J (Reporting) CIK: 0002052524 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38650 | Film No.: 251324808